Mirum Pharmaceuticals, Inc.
MIRM
$44.39
-$0.88-1.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 61.20% | 42.93% | 89.37% | 107.68% | 119.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.20% | 42.93% | 89.37% | 107.68% | 119.07% |
| Cost of Revenue | 29.10% | -8.95% | 103.42% | 196.93% | 258.10% |
| Gross Profit | 72.34% | 72.08% | 85.54% | 87.87% | 93.07% |
| SG&A Expenses | 26.44% | 23.05% | 38.37% | 49.35% | 51.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.48% | 21.05% | 41.43% | 65.30% | 62.89% |
| Operating Income | 42.64% | 25.67% | 49.56% | 0.17% | 2.50% |
| Income Before Tax | 44.64% | 31.24% | 40.49% | 67.44% | 17.62% |
| Income Tax Expenses | 64.90% | -356.00% | 39.36% | 100.95% | 210.45% |
| Earnings from Continuing Operations | 41.94% | 33.28% | 39.65% | 66.72% | 16.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.94% | 33.28% | 39.65% | 66.72% | 16.10% |
| EBIT | 42.64% | 25.67% | 49.56% | 0.17% | 2.50% |
| EBITDA | 56.11% | 32.94% | 70.52% | 19.88% | 19.40% |
| EPS Basic | 44.27% | 42.60% | 48.09% | 73.15% | 32.64% |
| Normalized Basic EPS | 46.86% | -253.72% | 48.80% | 21.43% | 33.86% |
| EPS Diluted | 44.41% | 42.80% | 48.09% | 73.15% | 32.47% |
| Normalized Diluted EPS | 46.86% | -253.72% | 48.80% | 21.43% | 33.86% |
| Average Basic Shares Outstanding | 4.18% | 16.23% | 16.26% | 23.95% | 24.56% |
| Average Diluted Shares Outstanding | 4.18% | 16.23% | 16.26% | 23.95% | 24.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |